Publication Date
| In 2025 | 0 |
| Since 2024 | 0 |
| Since 2021 (last 5 years) | 0 |
| Since 2016 (last 10 years) | 0 |
| Since 2006 (last 20 years) | 1 |
Descriptor
| Drug Therapy | 2 |
| Pervasive Developmental… | 2 |
| Adolescents | 1 |
| Attention Deficit Disorders | 1 |
| Autism | 1 |
| Behavior Problems | 1 |
| Children | 1 |
| Comparative Analysis | 1 |
| Hyperactivity | 1 |
| Measures (Individuals) | 1 |
| Outcomes of Treatment | 1 |
| More ▼ | |
Source
| Journal of the American… | 2 |
Author
| Aman, Michael G. | 1 |
| Arnold, L. Eugene | 1 |
| Cook, Amelia M. | 1 |
| Cook, Edwin H., Jr. | 1 |
| Guter, Stephen J., Jr. | 1 |
| Hall, Kristy L. | 1 |
| Leventhal, Bennett L. | 1 |
| Owley, Thomas | 1 |
| Ramadan, Yaser | 1 |
| Salt, Jeff | 1 |
| Thompson, Susan | 1 |
| More ▼ | |
Publication Type
| Journal Articles | 2 |
| Reports - Research | 1 |
Education Level
Audience
Location
Laws, Policies, & Programs
Assessments and Surveys
| Aberrant Behavior Checklist | 2 |
What Works Clearinghouse Rating
Peer reviewedOwley, Thomas; Walton, Laura; Salt, Jeff; Guter, Stephen J., Jr.; Winnega, Marrea; Leventhal, Bennett L.; Cook, Edwin H., Jr. – Journal of the American Academy of Child and Adolescent Psychiatry, 2005
Objective: To assess the effect of escitalopram in the treatment of pervasive developmental disorders (PDDs). Method: This 10-week study had a forced titration, open-label design. Twenty-eight subjects (mean age 125.1 [+ or -] 33.5 months) with a PDD received escitalopram at a dose that increased weekly to a maximum dose of 20 mg as tolerated. The…
Descriptors: Measures (Individuals), Psychiatry, Drug Therapy, Pervasive Developmental Disorders
Atomoxetine for Hyperactivity in Autism Spectrum Disorders: Placebo-Controlled Crossover Pilot Trial
Direct linkArnold, L. Eugene; Aman, Michael G.; Cook, Amelia M.; Witwer, Andrea N.; Hall, Kristy L.; Thompson, Susan; Ramadan, Yaser – Journal of the American Academy of Child and Adolescent Psychiatry, 2006
Objective: To explore placebo-controlled efficacy and safety of atomoxetine (ATX) for attention-deficit/hyperactivity disorder (ADHD) symptoms in children with autism spectrum disorders (ASD). Method: Children ages 5 to 15 with ASD and prominent ADHD symptoms were randomly assigned to order in a crossover of clinically titrated ATX and placebo, 6…
Descriptors: Hyperactivity, Autism, Drug Therapy, Attention Deficit Disorders
